Portfolio company
Humane Genomics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops synthetic oncolytic viral therapies to treat cancer patients by engineering viruses that selectively infect and destroy malignant cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Synthetic biology-powered mRNA therapeutics
The company develops programmable mRNA therapies using synthetic biology genetic circuits to deliver precise treatments for patients with cancer and other complex diseases.
Theolytics
The company develops oncolytic viral immunotherapies for patients with solid tumours.
Exomnis Biotech
This company develops engineered bacteria as delivery vehicles for cancer immunotherapies, serving pharmaceutical companies and clinical researchers.
Stratosvir
This company develops viral immunotherapies for late-stage cancer patients to target solid tumours through systemic delivery and immune system activation.
Cell Design Labs
This biotherapeutics company develops programmable cell therapies for cancer patients by engineering immune cells with synthetic genetic circuits to improve precision and safety.
Siren Bio
This company develops immuno-gene therapies combining viral gene delivery and cytokine immunotherapy to treat solid tumours for cancer patients.
Vivere Oncotherapies
This company develops engineered cancer immunotherapies to help the immune systems of patients with solid tumours detect and destroy malignant cells.
genemedicine
This company develops oncolytic adenovirus therapies for cancer patients and provides drug delivery systems and manufacturing services to the biotechnology sector.
